-
公开(公告)号：US20150232514A1
公开(公告)日：2015-08-20
申请号：US14677581
申请日：2015-04-02
Applicant: BAXTER INTERNATIONAL INC. , BAXTER HEALTHCARE SA
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
Abstract translation: 本发明提供了结合组织因子途径抑制剂（TFPI），包括TFPI抑制肽的肽及其组合物。 肽可以用于抑制TFPI，增强凝血因子缺陷受试者中的凝血酶形成，增加受试者中的血块形成，治疗受试者的血液凝固障碍，纯化TFPI和鉴定TFPI结合化合物。
-
公开(公告)号：US20150037820A1
公开(公告)日：2015-02-05
申请号：US14331803
申请日：2014-07-15
Applicant: Celera Corporation
Inventor： Charles BIRSE , Steve RUBEN , Marcia LEWIS , Mehdi MESRI
IPC: G01N33/574
CPC classification number: G01N33/57423 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57488 , G01N33/57492 , G01N2333/8114 , G01N2333/96486 , G01N2800/56
Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
Abstract translation: 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。
-
3.发明授权公开(公告)号：US08663629B2
公开(公告)日：2014-03-04
申请号：US13571138
申请日：2012-08-09
Applicant: William Markland , Robert C. Ladner
Inventor： William Markland , Robert C. Ladner
CPC classification number: C07K14/8117 , A61K38/00 , C07K14/8114 , G01N2333/8114 , G01N2333/96455
Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
Abstract translation: 本发明提供了能够结合激肽释放酶的Kunitz结构域的新型蛋白质同源物; 编码这种新蛋白质的多核苷酸; 和含有这些多核苷酸的载体和转化的宿主细胞。
-
4.发明授权公开(公告)号：US08283321B2
公开(公告)日：2012-10-09
申请号：US12580903
申请日：2009-10-16
Applicant: William Markland , Robert C. Ladner
Inventor： William Markland , Robert C. Ladner
CPC classification number: C07K14/8117 , A61K38/00 , C07K14/8114 , G01N2333/8114 , G01N2333/96455
Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
Abstract translation: 本发明提供了能够结合激肽释放酶的Kunitz结构域的新型蛋白质同源物; 编码这种新蛋白质的多核苷酸; 和含有这些多核苷酸的载体和转化的宿主细胞。
-
5.发明授权Methods of identifying an agent capable of interfering with Rad9 dephosphorylation 有权鉴定能够干扰Rad9去磷酸化的试剂的方法公开(公告)号：US07384761B2
公开(公告)日：2008-06-10
申请号：US10220375
申请日：2001-03-02
CPC classification number: C07K14/4738 , C12N9/16 , C12Y301/03016 , G01N33/5011 , G01N33/6872 , G01N2333/4739 , G01N2333/8114
Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
Abstract translation: 本发明涉及对细胞周期有影响或与细胞周期有关的新型多肽，核酸和相关分子。 本文还提供了与异源多肽序列融合的本发明的载体和宿主细胞多肽，与本发明的多肽结合的抗体和用于产生本发明的多肽的方法。 本发明还提供了鉴定介导细胞周期生物活性的新型组合物的方法，以及这些组合物在疾病诊断和治疗中的应用。
-
Patent Agency Ranking
公开(公告)号：US20170153238A1
公开(公告)日：2017-06-01
申请号：US15346547
申请日：2016-11-08
Applicant: Celera Corporation
Inventor： Charles BIRSE , Steve RUBEN , Marcia LEWIS , Mehdi MESRI
IPC: G01N33/574 , C12Q1/68
CPC classification number: G01N33/57423 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57488 , G01N33/57492 , G01N2333/8114 , G01N2333/96486 , G01N2800/56
Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
-
公开(公告)号：US08450275B2
公开(公告)日：2013-05-28
申请号：US13026070
申请日：2011-02-11
Applicant: Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
Inventor： Michael Dockal , Rudolf Hartmann , Markus Fries , Friedrich Scheiflinger , Hartmut Ehrlich , Ulrich Reineke , Frank Osterkamp , Thomas Polakowski
IPC: A61K38/57
CPC classification number: A61K38/10 , A61K38/00 , A61K2121/00 , C07K1/14 , C07K7/08 , C07K14/00 , C07K14/8114 , G01N33/68 , G01N2333/745 , G01N2333/8114 , G01N2333/96444 , G01N2333/96447 , G01N2500/02 , G01N2500/04 , G01N2500/20 , G06F19/16 , G06F19/18
Abstract: The invention provides peptides that bind Tissue Factor Pathway Inhibitor (TFPI), including TFPI-inhibitory peptides, and compositions thereof. The peptides may be used to inhibit a TFPI, enhance thrombin formation in a clotting factor-deficient subject, increase blood clot formation in a subject, treat a blood coagulation disorder in a subject, purify TFPI, and identify a TFPI-binding compound.
-
8.发明授权公开(公告)号：US07628983B2
公开(公告)日：2009-12-08
申请号：US11365438
申请日：2006-03-01
Applicant: William Markland , Robert C. Ladner
Inventor： William Markland , Robert C. Ladner
CPC classification number: C07K14/8117 , A61K38/00 , C07K14/8114 , G01N2333/8114 , G01N2333/96455
Abstract: This invention provides: novel protein homologous of a Kunitz domain, which are capable of binding kallikrein; polynucleotides that encode such novel proteins; and vectors and transformed host cells containing these polynucleotides.
Abstract translation: 本发明提供了能够结合激肽释放酶的Kunitz结构域的新型蛋白质同源物; 编码这种新蛋白质的多核苷酸; 和含有这些多核苷酸的载体和转化的宿主细胞。
-
公开(公告)号：US20090176228A1
公开(公告)日：2009-07-09
申请号：US12273994
申请日：2008-11-19
Applicant: Charles BIRSE , Marcia LEWIS , Steven Ruben , Mehdi Meari
Inventor： Charles BIRSE , Marcia LEWIS , Steven Ruben , Mehdi Meari
IPC: C12Q1/68 , G01N33/574
CPC classification number: G01N33/57423 , C12Q1/6886 , C12Q2600/106 , C12Q2600/112 , C12Q2600/118 , C12Q2600/136 , C12Q2600/158 , G01N33/57488 , G01N33/57492 , G01N2333/8114 , G01N2333/96486 , G01N2800/56
Abstract: Methods and compositions are provided for assessing (e.g., diagnosing), treating, and preventing diseases, especially cancer, and particular lung cancer, using lung cancer markers (LCM). Individual LCM and panels comprising multiple LCM are provided for these and other uses. Methods and compositions are also provided for determining or predicting the effectiveness of a treatment or for selecting a treatment using LCM. Methods and compositions are further provided for modulating cell function using LCM. Also provided are compositions that modulate LCM (e.g., antagonists or agonists), such as antibodies, proteins, small molecule compounds, and nucleic acid agents (e.g., RNAi and antisense agents), as well as pharmaceutical compositions thereof. Further provided are methods of screening for agents that modulate LCM, and agents identified by these screening methods.
Abstract translation: 提供了使用肺癌标志物（LCM）评估（例如诊断），治疗和预防疾病，特别是癌症和特定肺癌的方法和组合物。 为这些和其他用途提供了单个LCM和包含多个LCM的面板。 还提供了用于确定或预测治疗的有效性或使用LCM选择治疗的方法和组合物。 还提供了使用LCM调节细胞功能的方法和组合物。 还提供了调节LCM的组合物（例如拮抗剂或激动剂），例如抗体，蛋白质，小分子化合物和核酸试剂（例如RNAi和反义剂），以及其药物组合物。 还提供了筛选调节LCM的试剂的方法以及通过这些筛选方法鉴定的试剂。
-
10.发明申请Cell cycle proteins associated with rad9, compositions and methods of use 有权与rad9相关的细胞周期蛋白，组合物和使用方法公开(公告)号：US20070238134A9
公开(公告)日：2007-10-11
申请号：US10220375
申请日：2001-03-02
CPC classification number: C07K14/4738 , C12N9/16 , C12Y301/03016 , G01N33/5011 , G01N33/6872 , G01N2333/4739 , G01N2333/8114
Abstract: The present invention is directed to novel polypeptides, nucleic acids and related molecules which have an effect on or are related to the cell cycle. Also provided herein are vectors and host cells comprising those nucleic acid sequences, chimeric polypeptide molecules comprising the polypeptides of the present invention fused to heterologous polypeptide sequences, antibodies which bind to the polypeptides of the present invention and to methods for producing the polypeptides of the present invention. Further provided by the present invention are methods for identifying novel compositions which mediate cell cycle bioactivity, and the use of such compositions in diagnosis and treatment of disease.
Abstract translation: 本发明涉及对细胞周期有影响或与细胞周期有关的新型多肽，核酸和相关分子。 本文还提供了包含那些核酸序列的载体和宿主细胞，包含与异源多肽序列融合的本发明的多肽的嵌合多肽分子，与本发明的多肽结合的抗体以及本发明的多肽的制备方法 发明。 本发明还提供了鉴定介导细胞周期生物活性的新型组合物的方法，以及这些组合物在疾病诊断和治疗中的应用。
-
-
-
-
-
-
-
-
-
Search Results
32
records
(took 0.032 seconds)
